Providing comprehensive and timely information to our shareholders is important to us. The company has provided background information on our target diseases, the available clinical data, and our rationale for each Phase 3 study design, in the form of an investor webcast.

Pipeline Webcasts

Aprocitentan Phase 3 initiation

Aprocitentan Phase 3 initiation

In June 2018, Idorsia announced that the the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

Clazosentan Phase 3 advancing

Clazosentan Phase 3 advancing

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan. NB: An update was provided in October 2018, recruitment into the Japanese studies are now expected to continue into 2019.

ACT-541468 Phase 3 initiation

ACT-541468 Phase 3 initiation

In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of ACT-541468, a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia. NB: The proposed INN "nemorexant" was unsuccessful and will no longer be used in association with ACT-541468.

Lucerastat Phase 3 inititation

Lucerastat Phase 3 inititation

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.